TABLE 6.

In vitro susceptibilities of non-Candida yeasts to fluconazole and voriconazole as determined by CLSI disk diffusion testing: ARTEMIS DISK Surveillance Program, 2001 to 2003^a

Species	Susceptibility
	Fluconazoleb			Voriconazoleb
	n	%S	%R	n	%S	%R
Cryptococcus neoformans	1,281	79.1	9.8	1,266	97.2	11.7
Cryptococcus spp.c	50	68.0	16.0	50	86.0	10.0
Saccharomyces cerevisiae	413	86.9	6.8	401	94.8	3.2
Trichosporon spp.d	291	80.8	11.3	270	92.9	2.6
T. beigelii/T. cutaneum	80	73.8	15.0	78	79.5	15.4
T. mucoides	14	100.0	0.0	14	100.0	0.0
T. asahii	6	50.0	33.3	6	66.7	33.3
Rhodotorula spp.e	139	30.9	65.5	137	43.1	51.1
Blastoschizomyces capitatus	55	76.4	16.4	55	89.1	5.5
Pichia spp.f	27	81.5	11.1	26	100.0	0.0
Hansenula anomala	13	69.2	7.7	13	92.3	7.7

^aIsolates obtained from 115 institutions in 35 countries.

^bFluconazole and voriconazole disk diffusion testing was performed in accordance with CLSI M44-A. Interpretive breakpoints: S, ≥19 mm (fluconazole), ≥17 mm (voriconazole); R, ≤14 mm (fluconazole), ≤13 mm (voriconazole).

^cCryptococcus species other than C. neoformans.

^dTrichosporon species not otherwise identified.

^eRhodotorula species not otherwise identified.

^fPichia species not otherwise identified.